FDA Approves New Treatment Option for Eczema

The FDA has approved Eucrisa (crisaborole) ointment for the treatment of mild to moderate eczema (atopic dermatitis) in patients aged 2 years and older.

The ointment, applied twice daily, is a phosphodiesterase 4 inhibitor.

Its safety and effectiveness were evaluated in 2 placebo-controlled trials with 1522 participants aged 2 years to 79 years. Overall, those receiving Eucrisa were more likely to have clear or nearly clear skin at 28 days than those taking placebo.

Serious adverse effects of Eucrisa include hypersensitivity reactions. Common side effects include application site pain, burning, or stinging.

—Michael Potts


FDA. FDA approves Eucrisa for eczema [press release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm. December 14, 2016.